Medicus Pharma Ltd. Common Stock Total Assets
Medicus Pharma Ltd. Common Stock total assets. Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) holds total assets worth $19.11 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Medicus Pharma Ltd. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Medicus Pharma Ltd. Common Stock (2010–2025)
Total assets of Medicus Pharma Ltd. Common Stock from 2010 to 2025. This chart illustrates how Medicus Pharma Ltd. Common Stock's total assets have evolved over time, based on quarterly financial data. See today's stock price for Medicus Pharma Ltd. Common Stock for real-time trading data and today's change.
Medicus Pharma Ltd. Common Stock - Asset Composition Analysis
Medicus Pharma Ltd. Common Stock Total Assets Breakdown (December 2025)
Medicus Pharma Ltd. Common Stock total assets breakdown as of December 2025. Medicus Pharma Ltd. Common Stock's total assets of $19.11 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Medicus Pharma Ltd. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Medicus Pharma Ltd. Common Stock (MDCX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medicus Pharma Ltd. Common Stock's current assets represent 98.3% of total assets in 2025, a decrease from 99.0% in 2010.
- Cash Position: Cash and equivalents constituted 86.5% of total assets in 2025, up from 0.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Medicus Pharma Ltd. Common Stock Competitors by Total Assets
Key competitors of Medicus Pharma Ltd. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €612.64 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
Medicus Pharma Ltd. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 1.29 | 4.64 |
| Quick Ratio | 1.57 | 1.29 | 4.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.33 Million | $2.45 Million | $78.45K |
Medicus Pharma Ltd. Common Stock - Advanced Valuation Insights
This section examines the relationship between Medicus Pharma Ltd. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.97 |
| Latest Market Cap to Assets Ratio | 1.01 |
| Asset Growth Rate (YoY) | 78.2% |
| Total Assets | $10.06 Million |
| Market Capitalization | $10.20 Million USD |
Valuation Analysis
Above Book Valuation: The market values Medicus Pharma Ltd. Common Stock's assets above their book value (1.01x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Medicus Pharma Ltd. Common Stock's assets grew by 78.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medicus Pharma Ltd. Common Stock (2010–2025)
The table below shows the annual total assets of Medicus Pharma Ltd. Common Stock from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.06 Million | +78.18% |
| 2024-12-31 | $5.65 Million | +198.29% |
| 2023-12-31 | $1.89 Million | +569.75% |
| 2022-12-31 | $282.65K | +260.00% |
| 2021-12-31 | $78.51K | +93.47% |
| 2017-12-31 | $40.58K | -98.65% |
| 2010-12-31 | $3.00 Million | -- |
About Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The com… Read more